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Abstract Venous thromboembolism (VTE) is a serious
and often fatal medical condition with an increasing inci-
dence. The treatment of VTE is undergoing tremendous
changes with the introduction of the new direct oral anti-
coagulants and clinicians need to understand new treatment
paradigms. This article, initiated by the Anticoagulation
Forum, provides clinical guidance based on existing
guidelines and consensus expert opinion where guidelines
are lacking. Well-managed warfarin therapy remains an
important anticoagulant option and it is hoped that anti-
coagulation providers will find the guidance contained in
this article increases their ability to achieve optimal out-
comes for their patients with VTE Pivotal practical ques-
tions pertaining to this topic were developed by consensus
of the authors and were derived from evidence-based
consensus statements whenever possible. The medical lit-
erature was reviewed and summarized using guidance
statements that reflect the consensus opinion(s) of all
authors and the endorsement of the Anticoagulation For-
um’s Board of Directors. In an effort to provide practical
and implementable information about VTE and its treat-
ment, guidance statements pertaining to choosing good
candidates for warfarin therapy, warfarin initiation, opti-
mizing warfarin control, invasive procedure management,
excessive anticoagulation, subtherapeutic anticoagulation,
drug interactions, switching between anticoagulants, and
care transitions are provided.
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Introduction
Warfarin sodium remains an effective option for treating
venous thromboembolism (VTE) despite a narrow thera-
peutic index, wide inter-patient dosing variability, predis-
position to drug and food interactions, and need for close
monitoring of the intensity of anticoagulation effect using
the international normalized ratio (INR) [1]. This chap-
ter will provide guidance for the optimal use of warfarin for
VTE treatment.
Background
Although clinical experience with warfarin spans over 6
decades, the evidence supporting consensus panel recom-
mendations for many operational aspects of warfarin
therapy is not strong [2]. As a result, warfarin therapy
management is suboptimal in many cases [1]. This is
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important because failure to achieve adequate anticoagu-
lation during VTE treatment predicts higher rates of sub-
sequent recurrence [3–6]. Failing to achieve a therapeutic
INR by day 5 of therapy also prolongs the inconvenience
and pain associated with overlapping parenteral anticoag-
ulation, and increases the length of hospitalization and
overall treatment costs [2, 7]. Nonadherence to warfarin
therapy during VTE treatment has also been associated
with increased risk for recurrent VTE events [8].
Methods
To provide guidance on the management of warfarin in
patients with VTE, we first developed a number of pivotal
practical questions pertaining to this topic (Table 1).
Questions were developed by consensus of the authors.
Guidance statements in this chapter were derived from
evidence-based consensus statements whenever possible
[2, 9–11]. The medical literature was reviewed for topics
and key words including, but not limited to, coumarins, self
care, point-of-care systems, administration and dosage,
medication therapy management, drug monitoring, phar-
macovigilance, sentinel surveillance, VTE, drug related
side effects and adverse reactions, case management,
patient care management, nomograms, algorithms, clinical
decision support systems, pharmacists, nurses, physician
assistants, and pharmaceutical services with a focus on
high quality cohort studies and randomized controlled trials
(RCTs) published since the most recent iteration of the
American College of Chest Physician’s Evidence-Based
Clinical Practice Guidelines on Antithrombotic Therapy
and Prevention of Thrombosis (AT9). Guidance provided
in this document is, whenever possible, based on the best
available evidence. For some issues, however, published
evidence is lacking, and in all instances, guidance
statements represent the consensus opinion(s) of all authors
and are endorsed by the Anticoagulation Forum’s Board of
Directors.
Guidance
(1) Who are good candidates for warfarin therapy vs the
direct oral anticoagulants?
Based upon its pharmacokinetics, ability to be moni-
tored, costs and other characteristics, warfarin may be the
preferred anticoagulant for some patients and should be
avoided in others.
Patients with renal dysfunction
Kidney disease is a risk factor for VTE [12]. In patients
with estimated creatinine clearance (CrCl) between 30 and
50 mL/min there was no significant difference in the pri-
mary efficacy outcomes of recurrent thromboembolism or
thromboembolism-related death with direct oral anticoag-
ulants (DOACs) versus warfarin and the risk of major
bleeding or the combined endpoint of major bleeding or
clinically relevant non-major bleeding was also similar
between treatments [13]. Little is known about the use of
DOACs in patients with an estimated CrCl\ 30 mL/min,
as these patients were excluded from clinical trials com-
paring DOACs to warfarin for VTE treatment [14–20].
Because warfarin’s clearance does not rely on the renal
route of elimination it is the preferred oral anticoagulant
option for patients with an estimated CrCl\ 30 mL/min
[1]. However, decreased anticoagulation stability requiring
more frequent and intensive management has been
observed in patients with chronic kidney disease [21].
Unfractionated heparin is less dependent upon renal elim-
ination than LMWH [22]. Therefore, UFH is preferred over
LMWH during warfarin initiation for acute VTE in patients
with severe renal impairment [9]. In general, RCTs com-
paring DOACs to warfarin employed the Cockroft–Gault
equation to estimate renal function, used actual body
weight, and did not round serum creatinine when estimat-
ing CrCl for the purposes of drug dosing and study
exclusion criteria [23]. Since there is no consensus
regarding which methodology most accurately predicts
renal function for drug dosing, it is reasonable to employ a
similar approach when selecting the most appropriate oral
anticoagulant strategy for a given patient.
Guidance Statement For patients with CrCl\ 30 mL/
min (estimated using the Cockroft–Gault equation) we
suggest warfarin is the preferred anticoagulant. We also
suggest vigilant monitoring including more frequent INR
testing and bleeding risk assessment in patients with
CrCl\ 30 mL/min.
Table 1 Guidance questions to be considered
Who are good candidates for warfarin therapy versus the direct
oral anticoagulants?
How should warfarin be initiated?
How can I optimize anticoagulation control?
How do I manage warfarin during invasive procedures?
How do I manage warfarin-induced over-anticoagulation and
bleeding?
How do I manage sub-therapeutic anticoagulation and recurrent
VTE?
How do I manage warfarin drug–drug and drug-dietary
interactions?
How do I switch between anticoagulants?
What is an appropriate follow-up and care transitions strategy?
How do I manage challenging clinical situations?
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Patients with poor medication adherence
Multiple daily dosing is known to decrease adherence [24].
Warfarin is administered once daily, as is edoxaban but
apixaban and dabigatran are each administered twice daily
[25–27]. Rivaroxaban is given twice daily for the first
21 days of acute VTE treatment, followed by once daily
dosing thereafter [28]. Routine INR monitoring can iden-
tify poor medication adherence during warfarin therapy as
out-of-range INRs often result from warfarin non-adher-
ence [29]. In addition, repeated nonadherence to INR
monitoring recommendations is easy to recognize and has
been associated with increased thromboembolic risk and
may therefore be a surrogate marker for non-adherence
with taking warfarin doses as instructed [30]. Warfarin has
a long half-life and isolated subtherapeutic INR excursions
do not appear to substantially increase the risk of throm-
boembolism [31].
Guidance Statement For patients with a history of poor
medication adherence we suggest warfarin is the preferred
oral anticoagulant. However, the requirement for routine
INR monitoring of warfarin may be less than ideal for
patients with restricted mobility, poor venous access, or
other barriers to successful INR monitoring unless they are
suitable candidates for self-testing at home using point-of-
care INR monitoring devices (see below).
Patients with bleeding risk factors
Compared to warfarin-based therapy (with heparin or
LMWH overlap during initiation), apixaban resulted in a
reduction in both major and clinically relevant non-major
bleeding during treatment for acute VTE [20]. However, no
difference in major bleeding was evident when dabigatran
(although there was less overall bleeding) and edoxaban
(showed less major plus clinically relevant non-major
bleeding) when compared to warfarin-based VTE therapy
[15, 18]. Interestingly, rivaroxaban was associated with
less major bleeding when compared to warfarin-based
therapy for treatment of PE, but not for DVT [16, 17].
Some of the bleeding associated with warfarin, dabigatran,
and edoxaban may be attributable to the parenteral therapy
used during initiation of therapy [15, 18].
It is unclear if DOACs should be used preferentially for
patients with multiple bleeding risk factors because
patients at high risk for bleeding were specifically excluded
from the pivotal clinical trials. The use of DOACs in high
bleeding risk patients is further complicated by a lack of
specific reversal agent should bleeding occur [32]. There
are several options to reverse warfarin in a bleeding
patient; including vitamin K, fresh frozen plasma (FFP),
and prothrombin complex concentrates (PCC) (see below)
[1]. Appropriate intervention with these agents can rapidly
normalize the INR in a bleeding warfarin patient. However,
post hoc analyses of all major bleeding outcomes in phase
III trials comparing warfarin and dabigatran did not indi-
cate greater risk of morbidity or mortality with dabigatran-
related bleeding compared to warfarin [33]. Nevertheless,
lack of understanding of how best to manage of DOAC-
related bleeding continues to challenge clinicians and
presents a barrier to their use in the setting of a high
bleeding risk patient in particular.
Guidance Statement In patients at high risk for bleeding
complications; warfarin has the advantage of a proven
antidote and DOACs have less major and/or clinically
relevant non-major bleeding. These factors need to be
incorporated into shared decision making with patients.
Patients taking drugs known to interact
Warfarin has many drug interactions, but dose adjustments
based on INR monitoring can facilitate titration of the
anticoagulant response following coadministration with
interacting drugs [1]; this option is not available for
DOACs. Drugs that inhibit or induce the P-glycoprotein
efflux transporter result in significant alteration in serum
concentrations of apixaban, dabigatran, edoxaban and
rivaroxaban [32]. Rivaroxaban and apixaban are also
metabolized by cytochrome P450 3A4 and influenced by
inhibitors and inducers of this hepatic microsomal enzyme
[32]. Package labeling provides some guidance regarding
how common drug interactions may be managed for the
DOACs. However, package labeling is limited to examples
of drugs with known interaction potential and should not be
considered a comprehensive list [34]. Therefore warfarin
may be preferred for patients taking drugs known to
interact with available DOACs or that have similar phar-
macokinetic profiles.
Combining antiplatelet therapy with any type of anti-
coagulant increases bleeding risk [1, 35]. Compelling
indications for concomitant antiplatelet therapy in patients
taking warfarin for VTE are rare and poorly defined.
Efforts should focus on limiting combined use to improve
the safety of anticoagulant therapy wherever possible.
Aspirin should not be added to anticoagulant therapy for
primary prevention of coronary artery disease (CAD),
including patients with diabetes (i.e. the ‘‘CAD equiva-
lent’’). In patients where combined anticoagulant-an-
tiplatelet therapy is unavoidable, protection of the gastric
mucosa with a proton pump inhibitor may be considered.
Guidance Statement When avoiding drugs known to
interact with a given anticoagulant is not an option, we
suggest that warfarin is preferred because dose adjust-
ments based on INR monitoring can facilitate titration of
the anticoagulant response.
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Patient preference and affordability
Patient preference is an important consideration in
selecting anticoagulation therapy for VTE treatment, and
is influenced by factors related to convenience, comfort
level, and the true out of pocket costs of a given anti-
coagulant. Clinicians should discuss with patients all
costs of anticoagulation therapy, including copays,
impact on drug coverage gaps and deductibles, charges
for injectable anticoagulants during therapy initiation (if
applicable), laboratory tests (including charges for tests
performed at out-of-plan laboratories during travel), time
away from work for laboratory visits, and transportation
costs. For many patients, warfarin will remain the least
expensive anticoagulant, even after non-medication costs
are factored in. Patients initiating warfarin must also be
willing and able to self-inject LMWH or fondaparinux
during initiation of therapy if they are not hospitalized,
or have a friend or family member assist with the
injections. In addition, adherence to INR monitoring and
dietary requirements is required. Cost-effectiveness
analyses have investigated the financial impact of
DOACs compared to conventional therapy for VTE
treatment from the payer perspective. Rivaroxaban was
cost-effective compared to enoxaparin and warfarin at a
willingness to pay threshold of $50,000 per quality-ad-
justed life year [36]. Most of the cost savings in this
analysis resulted from a shorter duration of stay during
the index VTE hospitalization.
Guidance Statement We suggest that anticoagulation
providers thoroughly discuss the advantages and disad-
vantages of available anticoagulants with patients and
initiate therapy for VTE based on appropriate selection
criteria and patient preference.
Patients who are pregnant or breastfeeding
Warfarin is a known teratogen and should not be used
during pregnancy for management of VTE. Women of
childbearing potential should be counseled to avoid
becoming pregnant during warfarin therapy [1]. Warfarin
therapy does not result in appreciable accumulation in
breast milk and poses minimal risk to breastfeeding infants
[37]. The DOACs are small molecules with potential to
cross the placenta during pregnancy and since they have
not been studied in human pregnancy they should be
avoided in this setting [38, 39]. The mainstay for VTE
treatment in pregnancy is LMWH although unfractionated
heparin (UFH) has also been used successfully [37, 40].
Guidance Statement For VTE treatment during preg-
nancy we suggest against using warfarin or DOACs. For
VTE treatment in breastfeeding mothers we suggest that
warfarin therapy is the best oral anticoagulant option.
Patients with antiphospholipid antibody syndrome
Monitoring warfarin therapy using the INR can be chal-
lenging in some patients with antiphospholipid antibody
(APLA) syndrome due to antibody interference with
phospholipid-based coagulation assays [41]. Not all
thromboplastin reagents are sensitive to these antibodies,
so efforts should be made to select reagents less prone to
APLA interference. Alternative tests, such as the chro-
mogenic factor X assay, are also available for monitoring
warfarin therapy in these special cases although test turn-
around time may be several days. Little information is
available regarding the use of DOACs, LMWHs, or fon-
daparinux in APLA syndrome and there have been case
reports of treatment failure among patients transitioning
between warfarin and DOACs for management of APLA
syndrome [42].
Guidance Statement For patients with VTE associated
with APLA syndrome, we suggest warfarin adjusted to a
target INR range 2.0–3.0 is the best option for long-term
treatment [43].
(2) How should warfarin be initiated?
Baseline laboratory measurements prior to warfarin
therapy should include an INR for monitoring anticoagu-
lant response, and a complete blood count with platelets.
Warfarin should be initiated as soon as possible following
diagnosis of VTE, preferably on the same day, in combi-
nation with UFH, LMWH or fondaparinux [9]. Individual
responses to warfarin vary based on factors such as inpa-
tient or outpatient status, age, genotype, concomitant
medications, and comorbidities; however, the initial dose
of warfarin should be 5 or 10 mg for most patients [1, 7].
Initial doses \5 mg might be appropriate in patients
[75 years, the malnourished, those with liver disease or
congestive heart failure, patients receiving medications
known to inhibit warfarin’s metabolism, or patients with a
high bleeding risk [1]. For patients sufficiently healthy to
be treated as outpatients, warfarin 10 mg daily for the first
2 days has been suggested [2]. Initial warfarin doses
[10 mg should be avoided [1]. Beginning on day three of
therapy, INRs should be measured daily and warfarin doses
adjusted to achieve an INR C 2.0 as soon after day 5 of
therapy as possible [9].
Daily INRs can be challenging for some patients due to
geographic barriers and physical limitations. These barriers
should be considered prior to anticoagulation initiation. In
circumstances where daily INR monitoring is not possible,
DOACs may be preferred. Dosing nomograms are avail-
able to assist with warfarin therapy initiation (Table 2);
however, a recent meta-analysis comparing the efficacy of
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10 and 5 mg warfarin nomograms among patients with
VTE did not conclusively demonstrate the superiority of
either approach for initiation of warfarin to achieve an INR
of 2.0–3.0 on the fifth day of therapy [7].
Small pilot studies evaluating the use of cytochrome
2C9 and vitamin K epoxide reductase (VKORC1) phar-
macogenomic information to guide initiation of warfarin
therapy demonstrated decreases in the time to reach a
stabilized INR within the target therapeutic range, increa-
ses in time spent within the therapeutic range during early
therapy, and decreases in the frequency of warfarin dose
adjustments [44]. Subsequent large RCTs failed to confirm
the clinical utility of pharmacogenomic testing [45–47].
The mean TTR during the first 12 weeks of warfarin
therapy (including patients receiving treatment for VTE)
was improved by a genotype-guided strategy in one RCT
(adjusted difference, 7.0 percentage points; 95 % confi-
dence interval, 3.3–10.6) and the median time to reach a
therapeutic INR was 21 days in the genotype-guided group
as compared with 29 days in the control group (p\ 0.001)
[46]. However, the fact that 21 days were required to
achieve a therapeutic INR using the genotype-guided
strategy should be troubling to clinicians striving to mini-
mize the duration of overlapping parenteral therapy at the
initiation of VTE treatment. The largest RCT to date (in-
cluding 1015 patient, over half receiving treatment for
VTE) found no differences in TTR (mean difference -0.2,
95 % CI -3.4 to 3.1) or a combined outcome of any
INR C 4.0, major bleeding or thromboembolism when a
genotype-guided strategy was compared to one that used
only clinical variables [47]. In a meta-analysis of 2812
patients enrolled in nine RCTs, a genotype-guided dosing
strategy did not result in improved TTR (mean difference
0.14, 95 % CI -0.10 to 0.39), fewer patients with an INR
greater than 4 (risk ratio 0.92, 95 % CI 0.82–1.05), or a
reduction in major bleeding or thromboembolic events
(risk ratios 0.60, 95 % CI, 0.29–1.22, and 0.97, 95 % CI,
0.46–2.05, respectively) compared with clinical dosing
algorithms [45]. Furthermore, pharmacogenomic testing is
not covered by many insurance plans including Medicare,
is unlikely to be cost effective for general patients, and test
results will likely not be available in time to affect initial
warfarin dosing selection; therefore, pharmacogenomic
testing to determine initial warfarin doses is not recom-
mended for most patients [2, 48].
Guidance Statements During warfarin initiation for
VTE treatment we suggest the following:
• Initiate warfarin as soon as possible following diagno-
sis of VTE, preferably on the same day, in combination
with UFH, LMWH or fondaparinux.
• The initial dose of warfarin should be 5 or 10 mg for
most patients.
• Beginning on day 3 of therapy, INRs should be
measured daily and warfarin doses adjusted to achieve
an INR C 2.0 as soon after day five of overlap therapy
as possible.
• We suggest against using pharmacogenomic testing to
determine initial warfarin doses for most patients.
(3) How can I optimize anticoagulation control?
Well-managed warfarin therapy reduces the risk of
adverse events including recurrent VTE and bleeding and
the costs associated with VTE treatment [1]. Common
factors linked to non-therapeutic INR results include
changes in dietary vitamin K intake, concomitant medica-
tions, non-adherence, initiation phase of warfarin therapy,
and changes in health status. Unfortunately, no reason can
be identified for nearly half of non-therapeutic INRs [49].
Suggestions for optimizing warfarin therapy addressing
these and other factors are discussed briefly below.
Computer-aided warfarin dosing decision support
A large observational study in Sweden showed that com-
puter-aided warfarin dosing improved the probability of the
next INR being in range in most cases compared to manual
dosing [50]. In another RCT, INR outcomes associated
with computer-aided warfarin dosing were non-inferior to
those resulting from a simple paper-based dosing algorithm
during maintenance warfarin therapy [51]. Computer-aided
dosing of warfarin therapy may be most appropriate for
high-volume centers, such as specialized anticoagulation
clinics [2]. In a large RCT evaluating the impact of using
Table 2 Example of a warfarin dose-initiation nomogram [107]
Day INR Warfarin dose (mg)
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computerized decision support on warfarin dosing provided
by experienced anticoagulation providers, the subgroup of
patients receiving treatment for VTE experienced
improved therapeutic INR control and clinical outcomes
[52].
Guidance Statement When determining warfarin doses
during VTE treatment we suggest using computer-aided
warfarin dosing programs or validated dosing algorithms
over an ad hoc approach.
Anticoagulation management services
Inpatient and outpatient anticoagulant management services
(AMS) evolved in order to address the challenges associated
with managing and coordinating warfarin therapy [2].
Hallmarks of AMS care include sophisticated patient
tracking systems, anticoagulation providers with specialized
knowledge and skill focused predominantly on managing
warfarin, comprehensive patient education, and outcome
evaluation and quality improvement activities [53]. Well-
coordinated follow up is especially critical during antico-
agulation therapy initiation, when warfarin is being over-
lapped with parenteral anticoagulation [54]. While the
evidence base supporting the superiority of AMS is not as
strong as many would hope, a meta-analysis of available
studies demonstrated improved clinical outcomes associated
with AMS compared to usual care (Table 3) [55].
For the individual physician without access to an AMS,
the burden of anticoagulation management is significant.
Education, tools, and tips are available on-line (e.g. The
National Blood Clot Alliance (http://www.stoptheclot.org);
The Anticoagulation Forum Centers of Excellence (http://
excellence.acforum.org); and Clot Care (http://clotcare.
com)). A standardized approach to warfarin dose initiation,
familiarity with available guidelines, and leveraging sup-
port staff to facilitate tracking and/or a reminder system to
monitor for patients who are overdue for INR lab work are
critical elements to a successful anticoagulation
management for individual prescribers [53]. An interven-
tion consisting of prescriber education, clinical decision
support, consultation triggers, and checklists helped to
improve inpatient VTE management in one study even
without an AMS [56].
Guidance Statement We suggest enrolling patients with
VTE in an AMS, but when such services are not available,
individual clinicians should strive to implement a similar
structured care process.
Patient self-testing and patient self-management
Portable fingerstick INR devices enable patients to engage
in self-testing and/or management at home [1, 2]. The
accuracy of INRs measured using fingerstick devices is
acceptable for clinical application when viewed within the
context of the inherent limitations of the INR as a coagu-
lation measure [57]. Patient self-testing (PST) involves
patients performing their own INR at home and reporting
their test results to a healthcare professional responsible for
making warfarin-dosing decisions. Patient self-manage-
ment (PSM) refers to properly trained, highly motivated
patients independently altering their dose of warfarin
therapy based on fingerstick INR results. In clinical trials
PST and PSM are associated with higher levels of satis-
faction with care, modestly improved therapeutic INR
control (2.71 % TTR improvement, 95 % CI -6.1 to
11.51 % for patients with mechanical heart valves; 5.13 %
improvement, 95 % CI 0.97–9.28 % for patients with atrial
fibrillation), and lower risk for thromboembolic compli-
cations compared to those managed by ‘usual care’ (hazard
ratio 0.51, 95 % CI 0.31–0.85), but RCTs evaluating PST/
PSM outcomes in VTE-specific cohorts are lacking [2, 58].
In a subset of ‘real-world’ patients with DVT engaging in
PST, those testing weekly had higher TTR (72.9 %) than
those testing less frequently (65.8 %) [59]. PST has been
used successfully in pediatric patients and may be associ-
ated with improved quality of life for these patients and
Table 3 Outcomes of anticoagulation management service versus usual care [55]
Outcomes Events in AMS/patients (%) Events in UC/patients (%) Risk ratio (95 % CI) I2 (%)
Major bleeding
RCTs 5/367 (1) 10/368 (3) 0.64 (0.18–2.36) 12.2
Non-RCTs 49/4619 (1) 91/4595 (2) 0.49 (0.26–0.93) 46.7
Thromboembolic
RCTs 8/367 (2) 11/368 (3) 0.79 (0.33–1.93) 0.0
Non-RCTs events 44/5335 (1) 133/5250 (3) 0.37 (0.26–0.53) 3.7
All cause mortality
RCTs 10/299 (3) 11/299 (4) 0.93 (0.41–2.13) 0.0
Non-RCTs 5671/88,480 (6) 44,763/633,499 (7) 0.85 (0.37–1.98) 15.7
AMS anticoagulation management service, UC usual care, CI, confidence interval, I2 measures the heterogeneity of pooled studies, RCT
randomized controlled trial
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their families [60–62]. Fingerstick INR devices are rela-
tively expensive, but limited coverage of the monitor and
testing strips is available for some patients, but not until
after 90 days of treatment has been completed in some
cases. The weekly INR monitoring generally used with
PST/PSM has been associated with increased cost com-
pared to traditional venipuncture monitoring [63].
Guidance Statement For treatment of VTE, we suggest
PST and PSM should be accompanied by patient education
and reserved for motivated patients who can demonstrate
competency with self-testing equipment.
Responding to slightly out-of-range INRs
For patients with previously stable INR control, the single
slightly out-of-range INR probably represents random
variation; therefore adjusting warfarin doses may not be
necessary and may in fact tend to destabilize the INR
leading to suboptimal control [64]. For patients with pre-
viously stable therapeutic INRs presenting with a single
out-of-range INR of B0.3 INR units below or above the
therapeutic range, continuing the current dose and retesting
the INR within 7–14 days may lessen the potential for
destabilizing INR control [2, 65, 66]. Warfarin dose
adjustments (increasing or decreasing the cumulative
weekly warfarin dose by 5-20 %) should be made for
persistently out of range INR values [50, 67]. The optimal
process for adjusting the weekly warfarin dose has not been
defined. Patients using a single strength of warfarin may
need to administer different doses on some days of the
week (e.g. one tablet Monday, Wednesday, and Friday and
one half tablet on all other days). Patients using multiple
warfarin strengths may be able to administer the same dose
each day by combining tablet strengths. The method cho-
sen should be individualized based on patient preference.
After a dose adjustment checking the INR during the next
2 weeks while a new warfarin steady state is being achieved
can help determine whether further intervention is needed.
Conservative dose adjustments can prevent overcorrection
and dose destabilization and more frequent INR monitoring
can ensure the return of therapeutic anticoagulation. Pre-
dicting when a new steady state is achieved after adjusting
weekly warfarin doses is difficult and may be particularly
problematic when patients require very low weekly doses
and achieving steady state may take greater than two weeks.
Evidence supporting skipping doses or administering one-
time ‘boost’ doses to patientswith slightly out-of-range INRs
is limited and this common practice should be discouraged
unless the out-of-range INR is associated with a temporary
risk factor (e.g. missed dose, concurrent illness, presence of
interacting drugs, dietary factors) [66].
Guidance statements For patients with previously
stable therapeutic INRs presenting with a single out-of-
range INR of B 0.3 INR units below or above the thera-
peutic range we suggest continuing the current warfarin
dose and retesting the INR within 7–14 days. We suggest
against the routine use of boost or skipped warfarin doses
for unexplained slightly out of range INRs.
(4) Howdo Imanagewarfarin during invasive procedures?
Managing warfarin for invasive procedures requires an
estimate of the risk of bleeding if warfarin is not inter-
rupted compared with the risk of thromboembolism if
warfarin therapy is interrupted [68]. A systematic review of
primarily observational studies showed no decrease in
thromboembolic events and an increase in bleeding asso-
ciated with the use of LMWH bridging [69]. Results of the
BRIDGE trial, a large randomized, controlled trial com-
paring to bridging with LMWH to placebo found that no
bridging was noninferior to perioperative bridging with
LMWH for the prevention of arterial thromboembolism
and also decreased the risk of major bleeding [70]. This
trial did not include patients with VTE. Observational data
from patients with VTE interrupting warfarin for invasive
procedures indicates that LMWH bridge therapy was
associated with an increased risk of bleeding and is likely
unnecessary for most of these patients as the risk for
recurrent VTE was not different between patients who
were and were not bridged. [71].
There is growing acceptance that the thromboembolic
risk associated with interrupting warfarin outweighs the
bleeding risk incurred by continuing warfarin during dental
work, cataract surgery, minor dermatologic procedures and
other procedures associated with minimal bleeding risk
[68, 72]. However, for procedures with high bleeding
potential, stopping warfarin 4–5 days prior to the proce-
dure is necessary to return the INR to near-normal values
(Table 4). The risk of recurrent VTE is low, even when
near-normal INR values are required prior to the proce-
dure; therefore most patients with VTE can safely interrupt
warfarin for invasive procedures without bridge therapy
[71]. Criteria for determining which patients are at recur-
rent VTE risk high enough to require bridge therapy are not
well defined, but bridge therapy using LMWH has been
consistently associated with at least a three-fold increased
risk for major bleeding [69–71, 73]. Therefore, considera-
tion of bridge therapy should be reserved for those at
highest recurrent VTE risk (e.g. VTE within the previous
month, prior history of recurrent VTE during anticoagu-
lation therapy interruption, undergoing a procedure with
high inherent risk for VTE such as joint replacement sur-
gery or major abdominal cancer resection) [71, 74]. Even
in these high-risk patients, the risk of bleeding associated
with LMWH bridging must be carefully considered [74].
The use of prophylactic rather than therapeutic dose
LMWH may also be considered.
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Guidance Statements For patients requiring invasive
procedures during warfarin therapy for VTE we suggest
the following:
• Careful coordination of periprocedural warfarin man-
agement involving the anticoagulation provider, person
performing the procedure, and the patient.
• Continuing warfarin during dental work, cataract
surgery, minor dermatologic procedures and other
procedures associated with minimal bleeding risk over
interrupting warfarin therapy.
• Stopping warfarin 4–5 days prior to the procedure to
return the INR to near-normal values for procedures
with high bleeding potential.
• No bridge therapy for most patients (exceptions might
include VTE within the previous month, prior history of
recurrent VTE during anticoagulation therapy inter-
ruption, undergoing a procedure with high inherent
risk for VTE such as joint replacement surgery or major
abdominal cancer resection).
(5) How do I manage warfarin-induced over-anticoag-
ulation and/or bleeding?
Most patients with asymptomatic INR elevations should
be managed simply by withholding warfarin therapy until
the INR has decreased to a safer level nearer the thera-
peutic range (see Question #3) [2]. Reversing anticoagu-
lation with vitamin K has not been shown to affect the risk
of major bleeding for asymptomatic INRs between 4.5 and
10 compared to withholding warfarin alone [75]. However,
withholding warfarin therapy alone may not lower high
INRs quickly enough in patients at high risk for bleeding or
when the return to a safer INR is expected to be delayed
(e.g. INR elevation due to interacting medications, in
patients taking low weekly warfarin doses, or those with
history of prolonged INR elevation) [64]. Vitamin K
2.5 mg administered orally is suggested for non-bleeding
patients with INRs[ 10 [76]. Orally administered vitamin
K is preferred over the intravenous route in the absence of
major bleeding [2]. Subcutaneously administered vitamin
K should be reserved as a last resort due to unpre-
dictable absorption [77].
Management of warfarin-associated major bleeding
should include general supportive care and bleeding site
interventions along with rapid reversal of anticoagulation
[2, 78]. Restoration of hemostasis with vitamin K requires
synthesis of new clotting factors by the liver, a process
requiring at least 6 h and more likely 12–24 h to have a
significant impact on lowering the INR. Infusion of FFP
replenishes functional clotting proteins more rapidly, but
requires blood-type cross matching, thawing prior to
administration, and large volumes in many cases which can
result in fluid overload especially in patients with heart
failure or renal dysfunction [79]. The estimated volume of
FFP needed to significantly reduce the INR, depending on
its degree of elevation, is between 15 and 30 mL/kg. PCC
contain concentrated lyophilized clotting proteins that do
Table 4 Suggested approach to warfarin therapy interruption for invasive procedures
Days from Procedure Anticoagulation management
7–14 days before Assess recurrent VTE and procedure-related bleeding risk
If high risk for VTE recurrence consider bridging with LMWH (unnecessary for most patients with VTE)
Obtain baseline INR and determine number of warfarin doses to hold prior to procedure
7 days before Stop aspirin or other antiplatelet therapy if deemed safe and necessary
4 or 5 days before Stop warfarin
2 or 3 days before Start LMWH if necessarya
Day before Give last dose of LMWH 24 h before procedureb
Verify INR is low enough to proceed with procedure
Give vitamin K 2.5 mg orally if INR above goal for procedure
Day of Resume usual maintenance warfarin dosec after procedure
1–3 days after Resume LMWH if necessaryd
Resume aspirin or other antiplatelet therapy once adequate hemostasis is verified
5 ? days after Stop LMWH once INR is therapeutic
a LMWH usually initiated approximately 72 h prior to the procedure
b Give only the morning dose of twice-daily therapeutic-dose LMWH and reduce once-daily therapeutic-doses by 50 %
c Using ‘‘booster’’ doses (e.g. 1.5–2 times the usual dose) for 1–2 days when resuming warfarin therapy may reduce time required to achieve
INR C 2.0 [108]
d Resume LMWH approximately 24 h after (e.g. the day after) the procedure for lower bleeding risk procedures; for high bleeding risk
procedures wait 48 to 72 h and ensure adequate hemostasis before resuming LMWH, or avoid LMWH completely [68, 109]
INR international normalized ratio, LMWH low-molecular-weight heparin
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not require thawing or blood-type cross matching, and can
be rapidly administered after reconstitution without risk of
fluid overload and with a negligible risk of viral trans-
mission and transfusion-related acute lung injury [79].
Three- and 4-factor PCC both contain factors II, IX, X, and
proteins C and S, but 3-factor PCCs contain little or no
factor VII while 4-factor PCC contains significant amounts
of factor VII. Four-factor PCC was shown to be non-in-
ferior to FFP for the outcome of hemostatic efficacy 24-h
following administration [80]. However, 4-factor PCC is
preferred over FFP due to more rapid reversal of antico-
agulant effect, ease of preparation and administration, and
less potential for volume overload [81]. Three-factor PCC
(with or without supplemental FFP as a source of factor
VIIa) can be used instead of 4-factor PCC if necessary.
Activated PCC, which contains factor VIIa in addition to
factors II, IX and X, may be associated with a theoretically
higher risk of thromboembolic events than non-activated
products [79]. Recombinant factor VIIa is not recom-
mended for warfarin reversal because it only replaces 1 of
the 4 clotting factors inhibited by warfarin and its high cost
[79]. Because the half-life of factor VIIa is only 6–8 h
compared to warfarin’s half-life of 36 h, both PCC and
FFP should be administered in combination with 5–10 mg
of vitamin K via slow IV injection to ensure sustained
warfarin reversal [2].
Guidance Statements For non-bleeding patients pre-
senting with an elevated INR we suggest the following:
• Withholding warfarin alone or in combination with
1.25–2.5 mg of oral vitamin K for INRs between 4.5
and 10.0.
• 2.5 mg of oral vitamin for INRs[ 10.0.
For warfarin-related major bleeding we suggest rapid
reversal of anticoagulation with 5–10 mg intravenous
vitamin K and 4-factor non-activated PCC in conjunc-
tion with general supportive care and bleeding site
interventions.
(6) How do I manage sub-therapeutic anticoagulation
and recurrent VTE?
Outside of the initial 30 days of VTE treatment, the risk of
thromboembolic events in patients with stable INRs experi-
encing a single sub-therapeutic INR value is not sufficiently
high to warrant bridge therapy with injectable anticoagulants
[31]. Management strategies for recurrent VTE during
ongoing anticoagulation dependon factors such asmedication
adherence, INR control in the period preceding the recurrent
event, presence of malignancy, and proximity to the initial
VTE event. Determining and correcting the causes of non-
adherence to anticoagulation therapy should occur for VTE
recurrence attributable to medication non-adherence. This
may involve switching to an alternative anticoagulant
depending on individual circumstances. It may not be neces-
sary to increase the targeted intensity of anticoagulation
therapy when a period of sub-therapeutic anticoagulation
precedes recurrent VTE. Conversely, increasing the targeted
anticoagulation intensity may be required for patients who
experience recurrent VTE despite therapeutic anticoagulation
[82]. Patients with cancer experiencing recurrent VTE during
warfarin therapy should be switched to LMWH [9, 83].
Guidance Statement For most patients with VTE and
subtherapeutic warfarin anticoagulation we suggest re-
establishing therapeutic anticoagulation as quickly as
possible without bridge therapy. For recurrent VTE not
associated with subtherapeutic warfarin anticoagulation
we suggest either increasing the target INR range or
switching to an alternative anticoagulant.
(7) How do I manage warfarin drug–drug and drug-di-
etary interactions?
Pharmacokinetic drug interactions with warfarin are
primarily related to drugs that inhibit or induce hepatic
metabolism via the cytochrome 2C9, 1A2, and 3A4
isoenzymes [1]. Pharmacodynamic interactions increase
the bleeding risk associated with warfarin by affecting
hemostasis, platelet function, or clotting factor catabolism
[84]. When drugs with known interaction potential are
added or discontinued during warfarin therapy, or there is
uncertainty regarding a drug’s potential to alter the
response to warfarin, more frequent INR testing should be
performed until INR stability is re-established [1, 84].
Incorporating drug interaction alerts into electronic health
records has been shown to improve the rate of subsequent
INR monitoring [85]. Acute infections or other changes in
health status (e.g. fever, heart failure, diarrhea, vomiting)
can alter warfarin response regardless of whether antibi-
otics are prescribed and should also prompt more frequent
INR monitoring [86].
Many foods contain sufficient vitamin K to reduce the
anticoagulation effect of warfarin if consumed repetitively
or in large portions [1]. Consistency in dietary vitamin K
intake should be stressed rather than abstinence, as high
daily intake of vitamin K has been associated with more
stable INR control [87]. Significant changes in dietary
vitamin K intake should prompt more frequent INR mon-
itoring similar to when interacting medication are co-
administered.
Guidance Statement Following co-administration of
drugs with the potential to interact with warfarin or sig-
nificant changes in dietary vitamin K intake we suggest
more frequent INR testing and warfarin dose titration as
needed until INR stability is re-established.
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Vitamin K supplementation
Changes in dietary vitamin K intake may influence INR sta-
bility during warfarin therapy and several studies evaluating
the impact of reducing fluctuations in dietary vitaminK intake
via daily low-dose vitamin K supplementation, have been
published [88–91]. These studies do not support daily sup-
plementation with low doses of vitamin K as a means to
improve therapeutic INR control or clinical outcomes during
warfarin therapy [2, 90, 92].
Guidance Statement We suggest against routine use of
daily low-dose vitamin K supplements as a means to
improve therapeutic INR control or clinical outcomes
during warfarin therapy.
(8) How do I switch between anticoagulants?
Transitions from warfarin to other anticoagulants are
described in the chapters providing guidance for parenteral
anticoagulants and DOACs and in Tables 5 and 6. Tran-
sitioning from other anticoagulants to warfarin is detailed
below.
Dabigatran
According to product labeling patients with a CrCl C
50 mL/min transitioning from dabigatran to warfarin
should initiate warfarin therapy and overlap with dabiga-
tran for three days at which point dabigatran should be
discontinued and warfarin doses adjusted to achieve an
INR C 2.0 as quickly as possible [25]. For patients with a
CrCl between 30 and 50 mL/min and 15 and 30 mL/min,
warfarin and dabigatran should be overlapped for two days
and one day, respectively [25]. However, achieving a
therapeutic antithrombotic effect takes much longer
prompting some experts to suggest at least 3 days of
overlap combined with measuring the INR just before the
next dose of dabigatran to limit any effect on the INR.
Using this method, dabigatran is stopped when the INR is
2.0 or higher. The safety and efficacy of this method
compared to the instructions provided in product labeling is
unknown.
Rivaroxaban, apixaban, and edoxaban
Rivaroxaban and, to a lesser extent apixaban and edoxaban,
prolong the INR making INR measurements unreliable
while transitioning to warfarin [26, 28, 93]. There are no
clinical trials to direct how best to switch patients from
these medications to warfarin. Product labeling suggests
stopping rivaroxaban, apixaban, or edoxaban and starting
warfarin in conjunction with a therapeutic dose of par-
enteral anticoagulant when the next DOAC dose is due and
overlapping therapy for at least five days and the INR
is C 2.0 [26, 28, 93]. This approach may be reasonable in
patients at high risk of VTE recurrence, but is probably
unnecessary for most patients with VTE. Alternatively,
warfarin and DOAC could be overlapped for 3 days fol-
lowed by measuring the INR just prior to the dose of
DOAC with the assumption of some DOAC influence on
the INR (rivaroxaban[ apixaban, edoxaban). The DOAC
can be discontinued once the INR is C2.0. The product
labeling for edoxaban suggests reducing the usual edoxa-
ban by half at the start of overlapping therapy and mea-
suring INRs at least weekly [93].
Guidance Statements If a patient with VTE requires a
switch from a DOAC to warfarin, we suggest one of the
following approaches:
• Follow the information contained in the applicable
product labeling.
• For patients at low risk of VTE recurrence, we suggest
avoiding LMWH bridge therapy.
• For patients at high risk of VTE recurrence, we suggest
overlapping apixaban, rivaroxaban, edoxaban, or
dabigatran with warfarin therapy for at least 3 days
combined with measuring the INR just before the next
DOAC dose to limit any DOAC effect on the INR and
discontinue DOAC therapy when an INR C 2.0 is
achieved.
(9) What is an appropriate follow-up and care transitions
strategy?
The appropriate length of time between INR tests (INR
recall interval) depends on prior INR stability and the
probability of events in the foreseeable future that might
affect the INR. When warfarin dose adjustments are neces-
sary, a cycle of more-frequent INR monitoring should be
completed until a consistent pattern of stable therapeutic
INRs can be re-established [2]. An analysis in the Veterans
Administration health care system suggested that the opti-
mal recall interval after INRs C 4.0 or B1.5 is within
7 days, and within 14 days following INRs 3.1–3.9 or
1.6–1.9 [94]. Choosing an INR recall interval that allows
sufficient time for dosing changes to be reflected by the next
INR will reduce the likelihood of introducing unwanted
variation in the INR response. The INR recall interval should
not exceed 3 days following an INR[ 5.0 and if vitamin K
is administered, the INR should be rechecked the next day to
minimize the risk of INR overcorrection [95]. During acute
VTE treatment when warfarin is being overlapped with
parenteral anticoagulation therapy, INRs should be checked
daily beginning on day three of therapy for at least three
more days and the INR isC2.0 [9]. During the first 3 months
of warfarin therapy for VTE, INR recall intervals should not
exceed 6 weeks. After 3 months, INR recall intervals of up
to 12 weeks are reasonable for patients demonstrating con-
sistently stable INRs [2].
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It is very common for patients with VTE to transition
between healthcare settings at some point during antico-
agulation therapy. In patients admitted to the hospital for
initial treatment of VTE, the use of a pharmacist directed
inpatient anticoagulation service has shown improvements
in transitions of care communication with outpatient
physicians and anticoagulation staff and timeliness of INR
monitoring [96]. As many as 12 % of the more than 1.6
million Americans currently residing in nursing homes are
receiving long-term anticoagulant therapy with warfarin
and suboptimal communication between nursing home
staff and prescribing physicians has resulted in patient
safety issues [97]. Conversely, coordination of warfarin
therapy for nursing home residents by dedicated antico-
agulation providers has been shown to improve INR con-
trol [98]. Facilitated telephone communication between
nurses and physicians using a structured approach has also
been shown to modestly improve the quality of warfarin
management for nursing home residents [97]. All patients
and their caregivers should receive patient-centered edu-
cation regarding warfarin use for VTE treatment (Table 7).
Particular attention should be focused on recognition of
high-risk situations that could compromise patient safety
(e.g. recurrent VTE symptoms, stroke symptoms after
incidental head trauma, symptoms indicative of internal
bleeding) [99]. Patients completing overlapping therapy
with warfarin and parenteral anticoagulation at home
should have access to a provider 24 h a day, 7 days a week
to facilitate addressing questions and concerns in a timely
manner [54]. Anticoagulation management services have
been shown to be beneficial in this regard [100].
Guidance Statements
• For patients requiring warfarin dose adjustments for
out of range INRs we suggest rechecking the INR within
7 days after INRs C 4.0 or B1.5, and within 14 days
following INRs 3.1–3.9 or 1.6–1.9.
• Following an INR[ 5.0 we suggest rechecking the INR
within 3 days.
• Following vitamin K administration for excessive
anticoagulation we suggest rechecking the INR the
next day.
• When warfarin is being overlapped with parenteral
anticoagulation therapy during initiation of acute VTE
treatment we suggest that INRs be checked daily
beginning on day 3 of therapy until the INR is C2.0.
• During the first 3 months of warfarin therapy for VTE we
suggest that INR recall intervals not exceed 6 weeks.
• For patients demonstrating consistently stable INRs
after 3 months of warfarin therapy for VTE we suggest
that INR recall intervals can be extended up to
12 weeks.
• When patients receiving warfarin for VTE therapy
transition between healthcare sites we suggest dedi-
cated anticoagulation providers assume responsibility
for care coordination using a structured approach.
• We suggest that all patients and their caregivers
receive patient-centered education regarding warfarin
use for VTE treatment at the initiation of therapy and
periodically thereafter.
Table 5 Switching to DOACs
Warfarin to DOAC
Dabigatrana Start when INR\ 2.0
Rivaroxabana Start when INR\ 3.0
Apixabana Start when INR\ 2.0
Edoxabana Start when INR B 2.5
LMWH to DOAC
Dabigatran Start DOAC within 0–2 h of the time
of next scheduled dose of LMWHRivaroxaban
Apixaban
Edoxaban
(iv) UFH to DOAC
Dabigatrana Start DOAC immediately after
stopping iv UFHRivaroxabana
Apixabana
Edoxabana Start Edoxaban 4 h after stopping iv
UFH
As a general rule, we suggest that as INR drops below 2.5, a DOAC
can be started
As a general rule, we suggest that each DOAC can be started within
30 min after stopping (iv) UFH
a Recommendations adapted from company’s package insert
Table 6 Switching to Warfarin
DOAC to warfarin
Dabigatrana Start warfarin & overlap with dabigatran;
CrCl C 50 mL/min, overlap 3 days
CrCl 30-50 mL/min, overlap 2 days
CrCl 15-30 mL/min, overlap 1 day
Rivaroxabana
Apixabana
Stop DOAC; start warfarin & LMWH at time of next
scheduled DOAC dose and bridge until INR C 2.0
Edoxabana For 60 mg dose reduce dose to 30 mg & start
warfarin concomitantly. For 30 mg dose reduce
dose to 15 mg and start warfarin concomitantly.
Stop edoxaban when INR C 2.0
As a general rule, we believe either approach (i.e. stop DOAC then
start LMWH & warfarin; or overlap warfarin with DOAC, measure
INR just before next DOAC dose and stop DOAC when INR C 2.0)
can be used for all DOAC to warfarin transitions
CrCl creatinine clearance
a Recommendations adapted from company’s package insert. Over-
lap intended to avoid under-anticoagulation while warfarin effect
developing. When DOAC overlapped with warfarin, measure INR
just before next DOAC dose since DOAC can influence INR
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(10) How do I manage challenging clinical situations?
Liver disease
Patients with liver disease receiving warfarin have poorer
anticoagulation control and more bleeding [101]. A 4-point
score system has been proposed to identify patients with
liver failure at higher risk for poor anticoagulation control
and bleeding during warfarin therapy (one point each for
albumin [2.5–3.49 g/dL] or creatinine [1.01–1.99 mg/dL],
and 2 points each for albumin [\2.5 g/dL] or creatinine
[C2 mg/dL]. Compared to patients without liver disease,
those with liver disease and a score of zero had modestly
lower TTR (56.7 %) but no increase in bleeding (hazard
ratio, 1.16; p = 0.59), whereas those with liver disease and
the worst score (4) had both poor control (29.4 %) and high
risk of bleeding (hazard ratio 8.53; p\ 0.001) [100].
Warfarin should not be used in patients with liver disease
who have multiple or serious medical comorbidities (e.g.
advanced pulmonary/heart disease, advanced stage hepa-
tocellular carcinoma, recent history of GI bleeding), history
of multiple falls, and inability to closely monitor antico-
agulation [102]. In patients where the risk/benefit is
Table 7 Warfarin patient education for venous thromboembolism therapy
General information regarding VTE and treatment goals
Anticoagulant medications prevent blood clots from growing larger while the body begins to dissolve the clot
The clot may completely dissolve with time, or may never go completely away; some people will have chronic pain and swelling in the
affected limb; people with one clot are at increased risk of future clots
Warfarin tablets take several days to begin working; LMWH or fondaparinux injections work right away and provide protection against
future clotting until warfarin is fully active
Warfarin tablets are taken for 3 months or longer to prevent blood clots from returning
It is important to take warfarin exactly as directed
Blood test monitoring
Regular blood tests called the international normalized ratio (INR) are required to make sure warfarin is working properly
The INR tells how quickly blood clots form
The goal INR range is between 2.0 and 3.0; risk for clotting is higher when INRs are less than 2.0, risk for bleeding is higher when INRs are
greater than 3.0; doses of warfarin are adjusted based on INR test results
Other blood tests may be needed during warfarin therapy to help detect internal bleeding
Warfarin information
Each strength of warfarin has a unique color; with each warfarin refill make sure new tablets are the same color; if not, ask the pharmacist
why
Warfarin should be taken at approximately the same time each day, preferably in the evening or at bedtime
Bleeding is the most common and serious side effect of warfarin; be careful to avoid injury
Warfarin has many drug interactions; always check with an anticoagulation provider before taking any new medications (including over-
the-counter medications and dietary supplements)
Foods with a lot of vitamin K like broccoli, spinach, and green tea may interfere with warfarin; do not avoid foods with vitamin K, but try to
maintain consistent dietary habits
Alcohol increases the risk for bleeding and interferes with warfarin therapy; no more than 1–2 drinks per day, and avoid binge drinking
Contact an anticoagulation provider if any of the following happen:
Bleeding from a cut or scrape that won’t stop
Blood in urine
Blood in stool
Nose bleeding that won’t stop
Increased swelling or pain in the area where the blood clot formed




Vomiting up blood or material that resembles coffee grounds
Black tarry-appearing stool
Severe headache of sudden onset
Slurred speech
DVT deep vein thrombosis, INR international normalized ratio, LMWH low-molecular-weight heparin
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Table 8 Summary of guidance statements
Question Guidance statement
(1) Who are good candidates for warfarin
therapy versus the direct oral anticoagulants?
For patients with CrCl\ 30 mL/min (estimated using the Cockroft–Gault equation) we suggest warfarin is the
preferred anticoagulant. We also suggest vigilant monitoring including more frequent INR testing and bleeding
risk assessment in patients with CrCl\ 30 mL/min
For patients with a history of poor medication adherence we suggest warfarin is the preferred oral anticoagulant.
However, the requirement for routine INR monitoring of warfarin may be less than ideal for patients with
restricted mobility, poor venous access, or other barriers to successful INR monitoring unless they are
suitable candidates for self-testing at home using point-of-care INR monitoring devices (see below).
In patients at high risk for bleeding complications; warfarin has the advantage of a proven antidote and DOACs
have less major and/or clinically relevant non-major bleeding. These factors need to be incorporated into shared
decision making with patients.
When avoiding drugs known to interact with a given anticoagulant is not an option we suggest that warfarin is
preferred because dose adjustments based on INR monitoring can facilitate titration of the anticoagulant
response.
We suggest that anticoagulation providers thoroughly discuss the advantages and disadvantages of available
anticoagulants with patients and initiate therapy for VTE based on appropriate selection criteria and patient
preference.
For VTE treatment during pregnancy we suggest against using warfarin or DOACs.
For VTE treatment in breastfeeding mothers we suggest that warfarin therapy is the best oral anticoagulant
option.
For patient with VTE associated with APLA syndrome, we suggest warfarin adjusted to a target INR range
2.0–3.0 is the best option for long-term treatment [43]
(2) How should warfarin be initiated? During warfarin initiation for VTE treatment we suggest the following:
Initiate warfarin as soon as possible following diagnosis of VTE, preferably on the same day, in combination
with UFH, LMWH or fondaparinux
The initial dose of warfarin should be 5 or 10 mg for most patients.
Beginning on day three of therapy, INRs should be measured daily and warfarin doses adjusted to achieve an
INR C 2.0 as soon after day five of overlap therapy as possible.
We suggest against using pharmacogenomic testing to determine initial warfarin doses for most patients.
(3) How can I optimize anticoagulation
control?
When determining warfarin doses during VTE treatment we suggest using computer-aided warfarin dosing
programs or validated dosing algorithms over an ad hoc approach
We suggest enrolling patients with VTE in an AMS but when such services are not available, individual clinicians
should strive to implement a similar structured care process.
For treatment of VTE, we suggest PST and PSM should be accompanied by patient education and reserved for
motivated patients who can demonstrate competency with self-testing equipment.
For patients with previously stable therapeutic INRs presenting with a single out-of-range INR of B 0.3 below or
above the therapeutic range we suggest continuing the current warfarin dose and retesting the INR within 7 to
14 days.
We suggest against the routine use of boost or skipped warfarin doses for unexplained slightly out of range INRs.
(4) How do I manage warfarin during invasive
procedures?
For patients requiring invasive procedures during warfarin therapy for VTE we suggest the following:
Careful coordination of periprocedural warfarin management involving the anticoagulation provider, person
performing the procedure, and the patient
Continuing warfarin during dental work, cataract surgery, minor dermatologic procedures and other procedures
associated with minimal bleeding risk over interrupting warfarin therapy
Stopping warfarin 4–5 days prior to the procedure to return the INR to near-normal values for procedures with
high bleeding potential.
No bridge therapy for most patients (exceptions might include VTE within the previous month, prior history of
recurrent VTE during anticoagulation therapy interruption, undergoing a procedure with high inherent risk for
VTE such as joint replacement surgery or major abdominal cancer resection)




(5) How do I manage warfarin-induced over-
anticoagulation and/or bleeding
For non-bleeding patients presenting with an elevated INR we suggest the following:
Withholding warfarin alone or in combination with 1.25 mg to 2.5 mg or oral vitamin K for INRs between 4.5
and 10.0.
2.5 mg of oral vitamin K for INRs[ 10.0.
For warfarin-related major bleeding we suggest rapid reversal of anticoagulation with 5 mg to 10 mg intravenous
vitamin K and 4-factor non-activated PCC in conjunction with general supportive care and bleeding site
interventions.
(6) How do I manage sub-therapeutic
anticoagulation and recurrent VTE?
For most patients with VTE and subtherapeutic warfarin anticoagulation we suggest re-establishing therapeutic
anticoagulation as quickly as possible without bridge therapy.
For recurrent VTE not associated with subtherapeutic warfarin anticoagulation we suggest either increasing the
target INR range or switching to an alternative anticoagulant.
(7) How do I manage warfarin drug–drug and
drug-dietary interactions?
Following coadministration of drugs with the potential to interact with warfarin or significant changes in dietary
vitamin K intake we suggest more frequent INR testing and warfarin dose titration as needed until INR stability
is re-established.
We suggest against routine use of daily low-dose vitamin K supplements as a means to improve therapeutic INR
control or clinical outcomes during warfarin therapy.
(8) How do I switch between anticoagulants? If a patient with VTE requires a switch from a DOAC to warfarin, we suggest one of the following approaches:
Follow the information contained in the applicable product labeling
For patients at low risk of VTE recurrence, we suggest avoiding LMWH bridge therapy
For patients at high risk of VTE recurrence, we suggest overlapping apixaban, rivaroxaban, edoxaban, or
dabigatran with warfarin therapy for at least three days combined with measuring the INR just before the next
DOAC dose to limit any DOAC effect on the INR and discontinue DOAC therapy when an INR C 2.0 is
achieved.
(9) What is the appropriate follow-up and care
transitions strategy?
For patients requiring warfarin dose adjustments for out of range INRs we suggest rechecking the INR within
7 days after INRs C 4.0 or B 1.5, and within 14 days following INRs 3.1 to 3.9 or 1.6 to 1.9
Following an INR[ 5.0 we suggest rechecking the INR within 3 days.
Following vitamin K administration for excessive anticoagulation we suggest rechecking the INR the next day
When warfarin is being overlapped with parenteral anticoagulation therapy during initiation of acute VTE
treatment we suggest that INRs be checked daily beginning on day three of therapy until the INR is C 2.0
During the first three months of warfarin therapy for VTE we suggest that INR recall intervals not exceed 6 weeks
For patients demonstrating consistently stable INRs after three months of warfarin therapy for VTE we suggest
that INR recall intervals can be extended up to 12 weeks
When patients receiving warfarin for VTE therapy transition between healthcare sites we suggest dedicated
anticoagulation providers assume responsibility for care coordination using a structured approach
We suggest that all patients and their caregivers receive patient-centered education regarding warfarin use for
VTE treatment at the initiation of therapy and periodically thereafter
(10) How do I manage challenging clinical
situations?
For patients with liver disease complicated by VTE we suggest against warfarin in patients with multiple or
serious medical comorbidities and inability to closely monitor anticoagulation
When warfarin therapy is deemed necessary in patients with liver disease we suggest a starting dose of 1 mg daily
with careful dose titration to achieve an INR between 2 and 3.
For patients with esophageal varices who require warfarin therapy we suggest banding of varices prior to
beginning therapy when possible.
To ensure patients on warfarin are not lost to follow up we suggest use of a systematic tracking process
For patients who miss scheduled INR tests we suggest the use of non-threatening reminders delivered via phone,
text message, email, or regular mail
For patients having difficulty following warfarin dose instructions we suggest anticoagulation providers explore
the use of pillboxes, calendars, diaries, electronic reminders, and written instructions as means to improve
adherence
When patients receiving warfarin therapy for VTE treatment travel outside of their healthcare system’s service
area we suggest the following:
Ensure that a sufficient supply of warfarin is available to cover the duration of travel
Make arrangements for ongoing INR monitoring.
Ensure a plan for ongoing communication between the patient and anticoagulation provider is in place
200 D. M. Witt et al.
123
deemed acceptable, warfarin should be initiated with a
dose of 1 mg daily and carefully titrated to achieve an INR
between 2 and 3. Esophageal varices should be banded
prior to initiating warfarin therapy to reduce the risk of
bleeding [102]. Portal vein thrombosis, a frequent com-
plication in patients with end stage liver disease, can be
safely managed through the careful use of warfarin therapy
[102].
Guidance Statements
• For patients with liver disease complicated by VTE we
suggest against warfarin in patients with multiple or
serious medical comorbidities and inability to closely
monitor anticoagulation.
• When warfarin therapy is deemed necessary in patients
with liver disease we suggest a starting dose of 1 mg
daily with careful dose titration to achieve an INR
between 2 and 3.
• For patients with esophageal varices who require
warfarin therapy we suggest banding of varices prior to
beginning therapy when possible.
Nonadherence
Repeatedly missing INR tests has been associated with an
increased risk for thromboembolic complications during
warfarin therapy [30]. A systematic process for tracking
patients (e.g. an electronic database or tickler filing system)
should be used to minimize the possibility that a patient on
warfarin therapy is lost to follow-up, even for a brief period
[53]. Patients who miss INR tests should receive non-
threatening reminders via phone, text message, email, or
regular mail. Patients at higher risk for bleeding or recur-
rent VTE should receive INR reminders as soon as possi-
ble. The reasons underlying nonadherence to INR
monitoring instructions should be investigated and reme-
died when possible. Careful consideration of medical-legal
implications should take place before patients who
repeatedly fail to adhere to INR monitoring instructions are
discharged from anticoagulation monitoring services and
returned to the care of the referring provider. Patients who
fail to follow warfarin dose instructions have a lower TTR
on average and are likely at increased risk for thrombosis
and potentially bleeding [29]. Pillboxes, calendars, diaries,
electronic reminders, and written instructions can help
patients remember to take their medications as prescribed
[103].
Guidance Statements
• To ensure patients on warfarin are not lost to follow up
we suggest use of a systematic tracking process.
• For patients who miss scheduled INR tests we suggest
the use of non-threatening reminders delivered via
phone, text message, email, or regular mail.
• For patients having difficulty following warfarin dose
instructions we suggest anticoagulation providers
explore the use of pillboxes, calendars, diaries, elec-
tronic reminders, and written instructions as means to
improve adherence.
Travel
Patients traveling during warfarin therapy should ensure a
sufficient supply of warfarin is available to cover the
duration of travel, and make arrangements for ongoing INR
monitoring if necessary [104]. Patients should clearly
understand their responsibility with regard to payment for
INR testing at laboratories outside of their health plan
service area. Patients should be aware of the implications
of changes in normal dietary habits and alcohol con-
sumption during travel, and what to do if symptoms of
bleeding or recurrent VTE should occur. The potential
effect of antibiotics prescribed for prevention of travel-
related illness should be carefully monitored [105]. For
patients traveling in areas without reliable access to a
pharmacy, it may be prudent to carry a supply of vitamin K
for reversing the effects of warfarin should the INR
become excessive [104]. Time zone differences should be
taken into account when planning communication between
patients and anticoagulation providers [104]. The impor-
tance of proper hydration and avoiding prolonged immo-
bility during long-haul air travel or car travel should also be
emphasized [106].
Guidance Statements When patients receiving warfarin
therapy for VTE treatment travel outside of their health-
care system’s service area we suggest the following:
• Ensure that a sufficient supply of warfarin is available
to cover the duration of travel.
• Make arrangements for ongoing INR monitoring.
• Ensure a plan for ongoing communication between the
patient and anticoagulation provider is in place.
Conclusion
Expanding anticoagulant therapy options for treating VTE
offer the potential for patients to receive more personalized
therapeutic plans than have heretofore been possible. Well-
managed warfarin therapy remains an important anticoag-
ulant option and it is hoped that anticoagulation providers
will find the guidance contained in this article increases
their ability to achieve optimal outcomes for their patients
with VTE (Table 8).
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